Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Akarna Therapeutics

Request full access

At Akarna, our mission is to develop best-­in-­class treatments for NASH and other chronic liver diseases

Cambridge, United StatesFounded 2014Biotech & Life Sciences

About Akarna Therapeutics

Akarna Therapeutics is a biotech startup dedicated to developing innovative treatments for Non-Alcoholic Steatohepatitis (NASH) and other chronic liver diseases. NASH is a severe form of fatty liver disease closely linked to diabetes and obesity, affecting around 30 million people with no approved therapies currently available. This condition is becoming increasingly common and poses significant health risks.

Akarna's primary focus is on creating drugs that activate the Farnesoid X Receptor (FXR). FXR is a crucial regulator of metabolic, inflammatory, and fibrosis pathways in the liver. By targeting FXR, Akarna aims to address the underlying causes of NASH, offering a potential breakthrough in treatment where none currently exists.

The company operates in the biopharmaceutical market, specifically targeting liver diseases. Its clients include healthcare providers, medical researchers, and ultimately, patients suffering from NASH and related conditions. Akarna's business model revolves around research and development (R&D) of new drugs, followed by clinical trials, regulatory approval, and eventual commercialization. Revenue is generated through the sale of these approved drugs, partnerships with larger pharmaceutical companies, and potentially through licensing agreements.

Akarna's commitment to finding a cure for NASH positions it as a key player in the fight against this growing health issue. By focusing on FXR activators, the company aims to bring effective and much-needed treatments to market, improving the lives of millions of patients.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
56.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Sep 2016 $0 — Allergan —
SERIES B✓Equity / VC Feb 2016 $15M $60M Third Point Ventures · Forbion Capital Partners · New Science Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Akarna Therapeutics website traffic

Latest recorded traffic for Akarna Therapeutics is 0 monthly website visits, down 100% over the last three months.

Latest monthly visits0 3-month web change-100%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Akarna Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Akarna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Forbion Capital Partners
  • Third Point Ventures
  • New Science Ventures

Other known investors1 additional known investor

  • Allergan
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Akarna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Akarna Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.